Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA

Detalles Bibliográficos
Autores principales: Schjesvold, Fredrik H, Bakker, Nicolaas A, Sonneveld, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468451/
https://www.ncbi.nlm.nih.gov/pubmed/36087383
http://dx.doi.org/10.1016/j.tranon.2022.101528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468451/
https://www.ncbi.nlm.nih.gov/pubmed/36087383
http://dx.doi.org/10.1016/j.tranon.2022.101528

Ejemplares similares